论文部分内容阅读
拉米夫定的临床应用已有较长时间,从拉米夫定治疗中获益的患者亦不断增加,但也有一些患者停药后复发。现本人将治疗获完全应答的慢性乙型肝炎按维持疗程的长短分组,以了解慢性乙肝停药后复发率与疗程是否相关,为防止复发提供客观的临床依据。1资料和方法1.1研究对象48例慢性乙肝患者系1999-2001年我院门诊和住院病人,入院前病程为6个月-13年,平均年龄(7.5±1.5)年,其中男30例,女18例,年龄9-65岁,平均年龄(39.5±11.2)岁,诊断依据2000年病毒性肝炎诊断标准,以及“拉米夫定临床应用指导意见”的要求,血清HBsAg阳性,HBeAg阳性,HBV-DNA阳性,治疗前3个月内血清ALT增高超过正常1.5-10.0倍以内,排除重叠其他肝炎病毒感染及治疗前6个月内使用过抗病毒药物者,治疗前患者被告知
The clinical application of lamivudine has been a long time, patients who benefit from lamivudine treatment are also increasing, but there are some patients relapse after stopping. Now I will be treated fully responded to chronic hepatitis B according to the length of the treatment group, in order to understand the relapse rate after chronic hepatitis B is related to the course of treatment, to provide an objective clinical basis for the prevention of recurrence. 1 Materials and Methods 1.1 Subjects 48 cases of chronic hepatitis B patients from 1999 to 2001 outpatient and inpatient hospital, pre-admission course of 6 months to 13 years, mean age (7.5 ± 1.5) years, 30 males and 30 females 18 cases, aged 9-65 years, average age (39.5 ± 11.2) years old, the diagnosis based on the 2000 diagnostic criteria for viral hepatitis, and “lamivudine clinical application guidance” requirements, serum HBsAg positive, HBeAg positive , HBV-DNA positive, within 3 months before treatment serum ALT increased more than normal within 1.5-10.0 times, excluding the overlap of other hepatitis virus infection and the use of anti-viral drugs within 6 months before treatment, patients were informed before treatment